Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Immuneering (IMRX) announced a clinical supply agreement with Regeneron Pharmaceuticals (REGN) for its anti-PD-1 therapy, Libtayo. The supply ...

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

My colleague Clarissa Jan-Lim wrote a great explainer on the Trump administration's efforts to root out DEI programs from the federal government, including a memo demanding a plan to fire federal ...

How a new framework built around fairness, access, inclusion, and representation can succeed where DEI has failed. by Lily Zheng The need for more inclusive workplaces for all is undeniable — 91 ...

The memorandum, issued by the Office of Personnel Management on Tuesday, is a part of President Donald Trump’s aggressive reversal of the federal DEI policies of his predecessor. Federal ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

The FBI shuttered its diversity, equity and inclusion (DEI) office last month, according to the law enforcement agency. “In recent weeks, the FBI took steps to close the Office of Diversity and ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

I hear from them all the time. “Add one more to your list of aggrieved white males,” a reader wrote to me recently. The man, a 64-year-old electrical engineer in Florida, said a manager at ...